Formation of Antibodies to Factor VIII in Patients with Hemophilia a Who Are Treated with Interferon for Chronic Hepatitis C

Annals of Internal Medicine

Volumn 125, Issue 4, 1996, Pages 297-299

  Mauser Bunschoten, Eveline P ^a   Damen, Marjolein ^b   Reesink, Henk W ^c   Roosendaal, Goris ^a   Chamuleau, Robert A F M ^d   Van Den Berg, H Marijke ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b CENTRAL LABORATORY   (Netherlands)

^c Rode Kruis Bloedbank Amsterdam   (Netherlands)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; INTERFERON;

ANTIBODY PRODUCTION; ARTICLE; BLOOD COMPONENT THERAPY; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HEMOPHILIA A; HEPATITIS C; HUMAN; IMMUNOLOGY; MALE; MULTICENTER STUDY; NETHERLANDS; RANDOMIZED CONTROLLED TRIAL;

ANTIBODY FORMATION; BLOOD COMPONENT TRANSFUSION; CHRONIC DISEASE; FACTOR VIII; HEMOPHILIA A; HEPATITIS C; HUMANS; INTERFERONS; MALE; NETHERLANDS;

EID: 0030586451     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-125-4-199608150-00007     Document Type: Article

References (14)

1. Mauser-Bunschoten EP, Bresters D, van Drimmelen AA, Roosendaal G, Cuypers HT, Reesink HW, et al. Hepatitis C infection and viremia in Dutch hemophilia patients. J Med Virol. 1996;45:241-6.
2. Bresters D. Hepatitis C treatment. In: Reesink HW, ed. Current Studies in Hematology and Blood Transfusion. New York: Karger; 1994:121-36.
3. Renault PF, Hoofnagle JH. Side effects of alpha interferon. Semin Liver Dis. 1989;9:273-7.
4. Stricker RB, Barlogie B, Kiprov DD. Acquired factor VIII inhibitor associated with chronic interferon-alpha therapy. J Rheumatol. 1994;21:350-2
5. Castenskiold EC, Colvin BT, Kelsey SM. Acquired factor VIII inhibitor associated with chronic interferon-alpha therapy in a patient with haemophilia A. Br J Haematol. 1994;87:434-6.
6. McMillan CW, Shapiro SS, Whitehurts D, Hoyer LW, Rao AV, Lazerson J. The natural history of factor VIII:C inhibitors in patients with hemophilia A: a national cooperative study. II. Observations on the initial development of factor VIII:C inhibitors. Blood. 1988;71:344-8.
7. Mauser-Bunschoten EP, Bresters D, Reesink HW, Roosendaal G, Chamuleau RA, Haan E, et al. Effect and side-effects of alpha interferon treatment in hemophilia patients with chronic hepatitis C. Haemophilia. 1995; 1:45-53.
8. Bresters D. Detection of hepatitis C virus infection [Thesis]. Amsterdam: University of Utrecht; 1993:145-60.
9. Kasper CK, Aledort LM, Counts LB, Edson JG, Fratatoni J, Green D, et al. A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh. 1975;34:869-72.
10. Bouma BN, Starkenburg AE. Dilution of haemophilic plasma used as a reagent in the determination of anti-haemophilic factor A (factor VIII). Haemostasis. 1974;3:94-7.
11. Lee ML, Gomperts ED, Kingdom HS. A note on the calculation of recovery for factor VIII infusions [Letter]. Thromb Haemost. 1993;68:87.
12. Baron S, Tyring SK, Fleischmann WR Jr, Coppenhaver DH, Niesel DW, Kimpel GR, et al. The interferons. Mechanisms of action and clinical applications. JAMA. 1991;266:1375-83.
13. Dianzani F, Antonelli G, Capobianchi MR. The biological basis for clinical use of interferon. J Hepatol. 1990;11:S5-10.
14. Rosendaal FR, Nieuwenhuis HK, van den Berg HM, Heijboer HH, Mauser-Bunschoten EP, van der Meer J, et al. A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in The Netherlands. Blood. 1993;81:2180-6.